Posted on

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.Register here https://webinars.endpts.com/keeping-pace-with-the-evolving-global-landscape-in-vaccine-development/ Between 2017 and 2021, there were close to 1,400 industry-sponsored single country vaccine based clinical trials globally, with the Asia Pacific involved in over 45% of the trials. Download our latest data report here: Vaccines - Asia Pacific Clinical Trial Landscape. https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-trial-landscapeThe webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:- The COVID-19 impact on drug development and the regulatory landscape. - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage. - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.Date/Time: March 09 11:00 am - 12:00 pm ESTRegister here https://webinars.endpts.com/keeping-pace-with-the-evolving-global-landscape-in-vaccine-development/Panelists:SUSHANT SAHASTRABUDDHEASSOCIATE DIRECTOR GENERAL, INTERNATIONAL VACCINE INSTITUTE (IVI)Dr. Sushant Sahastrabuddhe, Associate Director General at the International Vaccine Institute (IVI), joined in July 2010, leading the clinical trials of IVI's typhoid vaccine and process to achieve its licensure, the global clinical development of and licensure of SK bioscience's COVID-19 vaccines and Phase 1 and 2 trials of Bharat Biotech's Chikungunya vaccine. As a vaccine enthusiast with more than 17 years of experience in multiple countries across diverse projects, he continues to lead collaborative efforts with companies and partners in Korea, India and globally to get these vaccines through early- to late-stages of their clinical development. Dr. Sahastrabuddhe is also the Associate Editor for Vaccines for tropical diseases and associated with Yonsei University as Research Professor and with Universite Claude Bernanrd, Lyon France as Research Fellow. In 2021, Dr. Sahastrabuddhe was named an 'Honorary Citizen of Seoul' for his contributions to the joint efforts with Korean companies and international partners to develop vaccines against COVID-19 and other diseases.PAUL GRIFFINASSOCIATE PROFESSOR, INFECTIOUS DISEASES PHYSICIAN, MICROBIOLOGIST, UNIVERSITY OF QUEENSLANDAn Infectious Diseases Physician and Microbiologist, Dr. Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013 and continues an appointment as an Associate Professor of Medicine at the University of Queensland Medical School. Additionally, Dr. Griffin chairs the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.Previously, Dr. Griffin was the Principal Investigator (PI) and Medical Director at Nucleus Network, a contract research organization specializing in infectious diseases trials, which included a PI role on in excess of 125 clinical trials predominantly in Infectious Diseases including novel vaccines and COVID-19 vaccines. With fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine, Dr. Griffin has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.BABAJI YADAVSENIOR CONSULTANT, NOVOTECH DRUG DEVELOPMENT CONSULTINGBabaji Yadav is a Senior Consultant with over eight years of academic experience in pre-clinical oncology drug development and eight years of industry experience in drug development. Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand. Previously he has worked as a Research Project Manager to oversee IND-enabling toxicology studies for lead oncology drugs and, prior to joining Novotech, was a Clinical Project Manager for early-phase oncology trials. Babaji is a UK Registered Toxicologist and at Novotech he is focused on providing technical toxicology advice and product development strategies to facilitate the entry of client's compounds into clinical trials. Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.JENNIFER ARELLANODIRECTOR OF CLINICAL SERVICES (PHILIPPINES), NOVOTECHJennifer Arellano is the Director of Clinical Services in the Philippines with over 25 years of technical and leadership experience in managing clinical trial operations for sponsors and CROs. With a Bachelor of Industrial Pharmacy from the University of the Philippines and a Pharmacist license, Jennifer's research operations experience includes monitoring, auditing, project leadership, feasibility, study start-up, driving inspection readiness and hosting regulatory inspection, client engagement and business development, learning & development and organization SOP development/review. Jennifer has contributed to the transformation of the Philippine clinical research industry - bringing improvement to the local clinical research regulations and practices and is the founding President of a non-profit organization, the Philippine Clinical Research Professionals Inc, with more than 400 members from pharmaceutical and CROs, and has more recently, volunteered pro-bono services during the Covid-19 pandemic to provide trial management consultancy to the Philippine DOH-funded trials such as WHO Solidarity COVID-19 Treatment and Vaccine trials, Avigan COVID-19 treatment trial, and Philippine Heart Association funded cardiovascular outcome study.Novotech has recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is the recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. About Novotech (Novotech-CRO.com)Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2,700 staff working across offices in 20 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Fuel Cell Bus Trials on the BRT Hikoboshi Line

TOKYO, Feb 8, 2023 - (JCN Newswire via SEAPRWire.com) - Fukuoka Prefecture, Commercial Japan Partnership Technologies Corporation (CJPT), and Kyushu Railway Company (JR Kyushu) have entered an agreement to conduct trials of a small fuel cell electric bus (FC bus) that runs on hydrogen, an environmentally-friendly next-generation energy source, on the BRT Hikoboshi Line (officially "Hitahikosan Line BRT"), a bus rapid transit system planned for launch around the summer of 2023.This initiative will be the first implementation of the partnership agreement between Fukuoka Prefecture and CJPT, entered into on December 26 last year, to expand commercial FC mobility and create a sustainable hydrogen society with the aim of achieving carbon neutrality. Fukuoka Prefecture and CJPT will work with JR Kyushu to hold the trials with a view to bringing FC mobility to local transportation.With the cooperation of communities along the line, JR Kyushu is working toward the launch of the BRT Hikoboshi Line, which is under development based on the concept of being "kind to people, communities, and the future." Expectations are that the trials of a next-generation small FC bus will further advance efforts toward regional development as an environmentally friendly transportation option.Going forward, Fukuoka Prefecture, CJPT, and JR Kyushu will collaborate in preparing to launch the trial runs as follows.1. Overview of the initiativeTrial runs for the practical application of next-generation small FC buses that run on hydrogen energySignificance and aims of the trials- The trials aim to deepen awareness of hydrogen as a future energy source by using it to operate a local transportation system familiar to residents while achieving region-wide sustainable growth.- By verifying the feasibility of adopting FC mobility, the trials will increase the options for local transportation and help create a green transportation system.- While bringing the use of hydrogen to local transportation, the trials will lead to the development of areas along the Hitahikosan Line BRT.Roles of each partyFukuoka Prefecture: Overall coordination and support for improving the environment of the trial runs CJPT: Development planning for the next-generation hydrogen bus and coordination of the trial vehicle JR Kyushu: Operation of the trial vehicle on the BRT Hikoboshi Line2. Trial vehicleVehicle stylingDrawing on the image of hydrogen as an environmentally friendly energy, the trial vehicle is styled to reflect the blue skies prevalent along the route of the BRT Hikoboshi Line. The use of a pattern that depicts the flowing robes of Orihime―a name for star Vega and lover of Hikoboshi (the star Altair) from Japanese legend―creates a unified and original styling for all vehicles to operate on the BRT Hikoboshi Line.Vehicle overviewSmall FC bus 1 vehicle FC bus based on the Toyota Coaster, 20-seater(1) with actual seating for 14 (planned)Length x Width x Height 6,990 mm x 2,100 mm x 2,630 mm Second-generation FC system from Mirai FCEV, with outstanding environmental performance of zero CO2 emissions during operation(2)Trial periodApproximately fall 2023 to spring 2025 (planned)Additional informationDetailed information, including the start date and timetables of the trial to be conducted prior to the trial runs and the actual trial runs, will be announced at a later date.(1) Includes driver's seat(2) FC mobility options are environmentally friendly vehicles that use a chemical reaction between hydrogen and oxygen to generate electricity, which does not generate CO2 emissions during use.For more information, visit https://global.toyota/en/newsroom/corporate/38698094.html. Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Asia Pacific Cell & Gene Research: Novotech is Growing 50% Faster than ROW

SYDNEY, AU, Feb 3, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW. The majority of trials are in oncology, specifically for blood cancers, viral infections, and solid tumors.Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).The company recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.The acquisition means biotech clients can access Novotech's unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021. China shows a 15% faster growth rate than the ROW. After oncology, the majority of cell & gene trials are in infectious diseases, CNS, and cardiovascular diseases.In addition, the Asia Pacific is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022.Novotech CEO Dr. John Moller said: "Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital. Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, selected for the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.Download our latest data report:Evolution of Clinical Trials in the Asia Pacific Region Compared to the US and the EU5https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech (Novotech-CRO.com)Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2,700 staff working across offices in 20 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech is Gold Sponsor at Biotech Showcase 2023

SYDNEY, AU, Dec 20, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.Meetings can be scheduled via the PartneringOne portal. https://informaconnect.com/biotech-showcase/partnering/Novotech will share the Asia Pacific advantages for expedited clinical trials, where biotechs have access to Novotech's vast patient populations, strong local regulatory knowledge, extensive site and KOL networks, and reputation for data quality.Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific. According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.Download the report here https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lieThe report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. About Novotech - https://novotech-cro.comNovotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Data Shows 50% of New Trials Have Sites in Asia Pacific

SYDNEY, AU, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.Download the report here https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lieThe report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. In addition, analysis of trial growth trends found that Asia Pacific has also seen high phase-level growth over the 5-year analysis period to 2022.- Phases I and II were dominated by Asia Pacific, which served as a trial location in 57% and 49% of trials, respectively.- US and EU remained stable at approximately 20% at phases I through III.- RoW representation is low in phases I and II but on par with the US and EU in phase III.Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006. Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities. Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."In response to the Company of the Year Award announcement, Novotech CEO Dr. John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience. "Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution."Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.About Novotech - https://novotech-cro.comNovotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy

SYDNEY, AU, Nov 11, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, is sponsoring BioCentury-BayHelix East-West Summit 2022, and Novotech's Chief Commercial Officer Barry Murphy is Session Chair for the expert panel on How to Build and Finance an East-West MRCT Strategy Workshop at the Summit (14-16 November 2022).Novotech is sponsoring the Networking Reception and Dinner.Workshop details:Global Development Workshop: How to Build and Finance an East-West MRCT StrategyNovember 15, 20222:30 PM - (PACIFIC TIME ZONE) BioCentury-BayHelix East-West Summit 2022https://conferences.biocentury.com/china-healthcare-summit/schedulePanelists are:- PATRICIA KEEGAN, M.D.: Chief Medical Officer, Junshi Biosciences- KE LIU, M.D., PH.D.: Chief Development Officer, Marengo Therapeutics- ROGER LUO, PH.D.: Chief Development Officer, Overland Pharmaceuticals- PEONY YU, M.D.: Chief Medical Officer, Apollomics Inc.Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.Commenting on Novotech's experience, Chief Commercial Officer Barry Murphy said the right drug development pathway supports investor attraction and a successful clinical program."Local regulatory knowledge and expertise will accelerate early clinical programs, while a global perspective with a focus on US FDA and NMPA requirements, will support key market approvals. Strategies for an East-West MRCT include:- Companies should engage with the US FDA and NMPA early to confirm guidance on their clinical roadmap.- Biopharma companies should take advantage of China's revised regulatory framework around acceptance of foreign clinical trials data for drug approval, making it easier for foreign companies to enter the Chinese market. - For biopharma companies looking to enter China, China's pharmaceutical market has advantages such as conducting first-in-human trials (FIH) and utilization of overseas clinical trial data for clinical trial application (CTA) filing, leveraging expedited clinical development pathways for accelerating the approval process; implementation of the Marketing Authorization Holder (MAH) system, favourable government policies to enhance domestic and global innovation encourages foreign direct investments (FDIs) in R&D that benefit the overseas companies.Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China.The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech, with experienced clinical teams in China and the US, can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA and NMPA approval process, avoiding delays and additional costs.Novotech has operations across the Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late-phase biotech clinical research. The company has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership, and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia Contactcommunications@novotech-cro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech Selected as Scrip Awards Finalist for Best Full-Service CRO

SYDNEY, AU, Oct 7, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, joins a prestigious group of global CROs as a finalist in the Scrip Award for Best Full-Service CRO. This year the Award has been split into two categories to separate the full-service providers from the smaller CROs.According to the Scrip Award organizers: "The Award for the Best CRO acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies' experience in handling all aspects of clinical trials and other research. Today, the role of the CRO has gone beyond the traditional model of service-level agreements, to offer bespoke clinical trial and other strategies; and CROs are increasingly engaged in risk-sharing partnerships, or acting as a single-source developer, while also remaining committed to core strengths."The award judges are senior executives from biopharma and investment firms, and clinical research leaders.Novotech CEO Dr. John Moller said he was extremely pleased that Novotech has been selected as a finalist and thanked the global Novotech team for their hard work and commitment to a truly customer focused approach to accelerate clinical development. "This level of recognition is a credit to the team and shows our Asia Pacific centered, global operations are setting new standards for biotech CRO partnerships. Our deep experience, exceptional site and investigator relationships - which also translates to patient access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the full service, customer focused solutions that biotechs need."Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs and has also been selected for the Gene & Cell Therapy Excellence Award. The company also has more than 50 Leading Site Partnership agreements and hundreds of long-term site relationships across the Asia Pacific region. About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference

SYDNEY, AU, Sep 15, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference.Novotech has extensive experience in cell & gene therapy clinical trials across Asia Pacific. The Asia Pacific accounts for over a third of cell & gene therapy trial activity with China being the leading location in APAC. In addition, APAC has nearly a 50% faster growth rate in cell & gene therapy trials than ROW. Blood cancers (ALL, NHL, DLBCL, lymphomas), solid tumors, viral infections, liver and gastrointestinal tract cancers are the top indications in China-based cell & gene therapy trials between 2016 and 2021.Watch our recent Endpoints News webinar for more information:EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-Thttps://novotech-cro.com/webinars/evolution-cell-gene-therapy-china-case-universal-car-tThe award was presented to Novotech during the 6th Cell & Gene Therapy World Asia 2022 conference (14th - 15th September) at the Sheraton Towers, Singapore.Novotech CEO Dr. John Moller said, "We are extremely pleased our team has been recognized with this prestigious award at the 6th Cell & Gene Therapy World Asia 2022 conference. Cell & gene therapy is driving recent innovations in biotech and it is an honour to be recognized as the CRO at the forefront in Asia-Pacific supporting this vital clinical research. Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital. Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success."Novotech has recently also been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.Download our latest data reports here:EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech Novotech is the leading Asia-Pacific centered, globally capable, biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech at ESMO Congress 2022 – New Data Shows 100% Oncology Trials Growth in APAC

SYDNEY, Sep 5, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs.Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.The clinical data compiled by GlobalData for Novoteoch also found that: "By the end of 2021 40% of active immuno-oncology clinical trials involved at least one location in the Asia-Pacific region, with majority of trials conducted in China, followed by Australia, South Korea, Japan and Taiwan. In the APAC region, the proportion of oncology trials doubled during 2017-2021. In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy."Download the Reports Here:IMMUNO-ONCOLOGY - ASIA PACIFIC - CLINICAL TRIAL LANDSCAPE https://novotech-cro.com/whitepapers/immuno-oncology-asia-pacific-clinical-trial-landscapeEVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5 https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report

SYDNEY, Sep 2, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled "Evolution of Clinical Trials in the Asia Pacific Region". The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period."Download report here https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5In addition, the GlobalData research found that all phases of clinical trials in the region registered higher growth than both the US and the EU5.The region registered significantly higher growth than the US and the EU5 across all analysed therapeutic areas, including CNS diseases, cardiovascular diseases, gastrointestinal diseases, and infectious diseases, the latter of which witnessed the highest growth. There was also 100% growth in oncology trials during the same period.GlobalData analysis of this strong growth has been linked to a range of factors, including:- site availability, particularly for oncology trials, when compared to the US and Europe- lower operating costs- the pharmacogenomic profile of Asian populations as a key factor that requires Phase I data in local populations. "Add to the mix the ease of regulatory compliance as well as the high standards required, and overseas drugmakers have never been keener to access this burgeoning market," according to GlobalData. "Recent streamlining of drug approval by the government, guided by the National Health Commission (NHC) and National Medical Products Administration (NMPA), has also resulted in a more efficient and clear-cut drug approval system based on global standards."According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance. In addition, experienced CRO operations across APAC and the US offer a unique and unparalleled suite of services for early to late phase biotech clinical research."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years. About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech’s Flexible Work Policy is Finalist in Best Workplace Flexibility Program “Excellence Award 2022”

SYDNEY, Jul 25, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, has been recognised for its innovative approach to workplace flexibility. Novotech CEO Dr. John Moller said: "Our flexible workplace design, information technology infrastructure, and flexible resourcing of projects are consistently delivering successful outcomes for our team members, clients, and all stakeholders. We are extremely pleased our workplace flexibility efforts are recognised by the Best Workplace Flexibility Program which has selected Novotech as an Excellence Awardee in 2022."Novotech Chief People Officer Angela Edwardson said that "over the last 12 months, Novotech has re-imagined what flexible working looks like for teams, clients, and the business. This renewed way of working incorporates flexible, remote, and in-office working options and aims to create a dynamic business environment and trusted culture. Team members can determine and apply the most effective way to work, unlocking the maximum value of their talent to benefit all stakeholders."Some of the new flexible working policies include:- FlexLocation: Work from home, office or other suitable location. - FlexTime: Flexible start/finish times - FlexBreak:Bbreaks during the day for wellbeing or other commitments. - FlexHours: An adjustment to contracted hours, either permanently or temporarily (ie: full-time to part-time). - FlexPlace: The option to work at other Novotech offices or cities/countries without a Novotech office temporarily. - FlexStudy: A combination of Flex options and/or leave to meet study commitments.- FlexHolidays: The option to select alternate dates in lieu of allocated celebration/public holidays. - FlexLeave: Leave can be taken by the hour and in combination with other leave types and flexible options. - FlexTimeout: Extended unpaid leave to pursue and interest, relax or attend to caring responsibilities- FlexPersonal: A combination of day-to-day and/or planned options. "Already 17 team members have used or are planning to use FlexPlace in 2022," said Edwardson. "Novotech has a large cohort of expatriate workers, and our new addition of FlexPlace supports them to re-connect with their families and friends or travel while still meeting their working requirements."Novotech's Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes.The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech Receives “Best Biologics CRO Award 2022” at Korea Bioprocessing Excellence Awards 2022

SEOUL, S.KOREA, Jun 29, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was today awarded the Best Biologics CRO Award at a ceremony as part of 11th Biologics Manufacturing Korea, the 6th Cell & Gene Therapy World East Asia, and the 3rd BioLogistics World Korea conferences (29th - 30th June 2022) which attract more than 300 representatives from Korea's top biopharmas, vaccine manufacturers, and biologics companies.Novotech Country Managing Director Sanghee Kim said the Korea team was extremely pleased to receive this award in recognition of the clinical excellence provided to clients in the biologics sector.Novotech Vice President Global Head Clinical Services Yooni Kim also said: "Novotech's Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions."Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, New Zealand, South Korea, Greater China, Southeast Asia, India, South Africa and the US.Novotech CEO Dr. John Moller said: "The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest-growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms have accelerated approval processes. The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs. Clients will receive a seamless service, with a unified approach to systems and SOPs," Moller said. About Novotech Health HoldingsNovotech Health Holdings Pte. Ltd. ("Novotech") is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech Receives CRO Leadership Award for Exceeding Customer Expectations

CHICAGO, IL, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was awarded a prestigious Clinical Leader and Life Science Leader CRO Leadership Award for exceeding customer expectations, at Drug Information Association 2022 (DIA 2022).Novotech CEO Dr. John Moller said the company was extremely pleased to receive this award for the second consecutive year. "Receiving this recognition from our clients is incredibly important to us and is an endorsement of our service delivery model that is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem solving, ownership and flexibility, and our investments in data and technology ensure clients have real time access to trial performance."Book a meeting with one of the Novotech experts at DIA here. https://novotech-cro.com/contactClinical Leader and Life Science Leader working with Industry Standard Research (ISR), selected Novotech for the CRO Leadership Award.According to the CRO Leadership Award research team: "The awards are based on customer feedback. Winning CROs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services. Primary market research by ISR Reports is the basis of the awards. Sponsors provide ratings of CROs based on recent outsourced projects. This experiential feedback is analyzed by sponsor company size to reveal leading CROs in different performance categories."Ed Miseta, Chief Editor for Clinical Leader said: "Selecting the right CRO can make or break your project. It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. Regardless of whether you are concerned about compatibility, capabilities, expertise, quality, or reliability. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. We are grateful to our colleagues at ISR Reports for conducting the research necessary to produce these awards. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for the work ethic they exhibit in consistently meeting the needs of their drug development clients."Kevin Olson, CEO of Industry Standard Research said: "Industry Standard Research (IRS) continues to consider it an honor to provide the primary market research data for Life Science Leader and Clinical Leader's CRO Leadership Awards. ISR's stringent screening process ensures that only highly qualified industry decision-makers participate in our CRO benchmarking market research. This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months. The data enable users of ISR's market research to make confident business decisions based on the experiences of their industry peers."Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies. Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.Novotech CEO Dr. John Moller said Novotech's Asia-Pacific and US teams support cost effective expedited clinical research with world-class data, and the most advanced technology including solutions that enable acceleration of clinical trials across the regions. "The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes. The expansion into the US was a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs."About Novotech Health Holdings Pte Ltd ("Novotech")Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech’s APAC and USA Leadership Teams at BIO 2022

SAN DIEGO, CA, Jun 14, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, will have key executives from APAC and the US attend BIO 2022 for meetings with biotechs considering the Asia-Pacific region to expedite their clinical trials. #4907Book a meeting with one of the Novotech experts at BIO here. https://novotech-cro.com/contactNovotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies. Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.Novotech CEO Dr. John Moller said Novotech's Asia-Pacific and US teams support cost effective expedited clinical research with world-class data, and the most advanced technology including solutions that enable acceleration of clinical trials across the regions. "The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes. The expansion into the US was a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs." Clients will receive a seamless service, with a unified approach to systems and SOPs," Moller said. According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5*, Over the last five years more than 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%). The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, lower cost of conducting studies, high-quality standards and the presence of top clinical sites.* https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech Health Holdings Novotech Health Holdings Pte. Ltd. ("Novotech") is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 3,700 clinical trials across a broad range of therapeutic areas. Novotech is well positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144USA: +1 415 951 3228ASIA: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China

SYDNEY, Jun 6, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, is sponsoring the Endpoints ASCO22 "Accelerating clinical development in China and the US".Register here https://asco22.endpts.com/TUESDAY, JUNE 711:00am - 11:45am ET (1:00 - 1:45 local time)Novotech Booth at ASCO #14115The virtual session will cover the latest on the clinical trial landscape and infrastructure in China and includes Novotech's DCT partner, Obvio Health, on DCT strategies for patient-centric, oncology study design and execution.According to the Endpoints ASCO session: "China and the US are the world's largest oncology research destinations, and the clinical research bridge between them supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications. With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs."The expert panel features:- Jin Li, Professor of the Department of Oncology, Shanghai East Hospital- Peter Luo, Co-Founder, Chief Executive Officer and Chairman, Adagene- Vivian Gu, Head of CDR China CMO Novotech- Nancy Snowden, Head of US Operations, Novotech- Susan Dallabrida, CEO and Chairman SPRIM, ObvioHealthModerated by: Arsalan Arif, Publisher & Founder Endpoints NewsChina offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations and world-class KLOs. According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5*, over the past 5 years the growth of oncology trials (CAGR of 25%) in China outpaced other countries. This growth was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immuno-oncology, and leadership in cell therapy. China also recorded the largest number of new trials, followed by the US. In China, the number of new trials doubled during 2017-2021. Notably, China's regulatory reforms have accelerated drug approval by reducing the overall review and process. In addition, over the last five years more 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%).The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, low cost of conducting studies, high-quality standards and the presence of top clinical institutions acting as sites. Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients. Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies. NCGS was established in 1984 in South Carolina and has a workforce of about 300 professionals across the US.Novotech CEO Dr. John Moller said: "This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs." "Clients will receive seamless service, with a unified approach to systems and SOPs," Moller said. Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China. Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data. Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.* https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech Health HoldingsNovotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144USA: +1 415 951 3228ASIA: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

NTT DOCOMO and NTT to Collaborate on 6G Experimental Trials with World-leading Mobile Technology Vendors

TOKYO, Jun 6, 2022 - (JCN Newswire via SEAPRWire.com) - NTT DOCOMO, INC. (DOCOMO) and Nippon Telegraph and Telephone Corporation (NTT) announced today that they will collaborate with world-leading mobile technology vendors Fujitsu, NEC, and Nokia to conduct experimental trials of new mobile communications technologies for the targeted commercial launch of 6G services by around 2030.Launching the envisioned 6G services will require verification of numerous new mobile technologies, including those needed to newly use frequencies in the millimeter and sub-terahertz (above 6 GHz) bands, in addition to bands for existing 5G services. The trials are also expected to verify AI-based wireless transmission methods. DOCOMO and NTT will jointly conduct experimental trials with the three vendors, focusing on mobile technologies using new 6G frequency bands and AI-based wireless technology among these various mobile technologies.The new 6G system will greatly exceed the performance of 5G and simultaneously provide high-speed, large capacity, and low latency capabilities, use new high-frequency bands such as sub-terahertz bands above 100 GHz, expand communication coverage in the sky, at sea and in space, and enable both ultra-low-power consumption and low-cost communications.The realization of 6G is one of the most important goals envisaged in the NTT group's Innovative Optical and Wireless Network (IOWN)* project for launching all-new communication infrastructure. Aiming to realize "5G Evolution & 6G powered by IOWN," DOCOMO and NTT are actively conducting 6G research and development combining NTT's optical and wireless technologies with DOCOMO's mobile technologies.Naoki Tani, Executive Vice President and Chief Technology Officer at DOCOMO, said: "6G studies are progressing two or three years ahead of that of 5G. From this early stage, we would like to collaborate with world-leading global vendors to proactively demonstrate breakthrough concepts and technologies and promote them to the world."DOCOMO and NTT will begin conducting indoor trials within the fiscal year ending in March 2023, and outdoor trials will begin in the following fiscal year. The trials are expected to verify concepts proposed so far by DOCOMO and NTT and will be reported in global research groups, international conferences and standardization activities related to 6G, and will serve as a foundation for more advanced technologies.Through their 6G trials with the three abovementioned vendors as well as other partners, DOCOMO and NTT look forward to accelerating the global standardization and commercialization of 6G.*Innovative Optical and Wireless Network (IOWN) is an advanced communications infrastructure incorporating cutting-edge photonics, computing and other technologies to realize a smarter world promoted by IOWN Global Forum (https://iowngf.org/).Partner Quotes:- FujitsuShingo Mizuno, EVP of Fujitsu Limited comments: "We are excited to start collaboration with DOCOMO and NTT to work toward the realization of practical applications for 6G. Fujitsu positions network technology as an essential element in its efforts to deliver business transformation through digital innovation and ultimately achieve a more sustainable society. We are confident that our involvement in the research and development of 6G technologies will contribute to solving societal issues in keeping with this vision of a sustainable future."- NECAtsuo Kawamura, Executive Vice President, NEC Corporation said: "We are pleased to expand our collaboration with DOCOMO and NTT in the development of 6G, which represents an important foundation that will accelerate the fusion of the digital and real world, connect things and experiences on a global scale, and provide new value to society. Moreover, this will contribute to the achievement of the NTT Group's IOWN initiative as we actively promote research and development toward the realization of 6G and a more prosperous society."- NokiaPeter Vetter, President Bell Labs Core Research, Nokia, said: "It is an honor for Nokia to collaborate with DOCOMO and NTT to jointly define and develop key technologies towards 6G. Nokia and DOCOMO have a long-lasting relationship in early joint research, and DOCOMO is always among the first operators to bring new generations to the market. We look forward to working together to validate AI native air interface and sub-terahertz proof-of-concepts that will help bring 6G to life."About NTT DOCOMONTT DOCOMO, Japan's leading mobile operator with over 83 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations. www.docomo.ne.jp/english/.About NTTNTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation. As a top 5 global technology and business solutions provider, our diverse teams operate in 80+ countries and regions and deliver services to over 190 of them. We serve over 80% of Fortune Global 100 companies and thousands of other clients and communities around the world. For more information on NTT, visit www.global.ntt/.Media Contact:NTT DOCOMOMr. Takuya Ori or Ms. Maria HisamatsuPublic Relations DepartmentTel: +81 (0)3 5156 1366Fax: +81 (0)3 5501 3408Website: www.docomo.ne.jp/englishOpen other windowNTT Information Network Laboratory GroupPlanning Department, Public Relations Sectionnttrd-pr@ml.ntt.com Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Fujitsu, NTT DOCOMO and NTT to start joint trials towards practical applications for 6G

TOKYO, Jun 6, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu today announced that it will start collaboration with NTT DOCOMO, INC. (hereinafter DOCOMO)(1) and Nippon Telegraph and Telephone Corporation (hereinafter NTT)(2) to conduct joint trials towards the realization of practical applications for 6G. In the joint trials, the partners will utilize radio waves in the high frequency range (sub-terahertz waves) of 100 GHz and 300 GHz, which represent promising candidates for use in 6G to realize a high-speed communication technology with radio wave propagation that is not affected by obstacles. The companies further aim to develop a high-frequency wireless device that utilizes a compound semiconductor(3).Figure: Image of the joint trialsFujitsu positions network technology as an essential element in its efforts to deliver business transformation through digital innovation and ultimately achieve a more sustainable society.Background and tasks6G networks are expected to further accelerate the digitization of society and provide essential solutions to complex societal issues. To this end, global R&D activities focus on further advancing the high-speed, large-capacity, low-latency, and simultaneous multi-connection features of current 5G networks and aim to realize communications with low power consumption with an eye towards the full-scale launch of 6G networks and services around 2030.Wider frequency bands play a significant role in realizing high-speed and large-capacity communication exceeding that of current 5G networks. 100GHz and above are promising frequency bands for 6G networks that would enable communication speeds of over 100 Gbps, which is ten times higher than that of current 5G networks. However, radio waves at higher frequencies tend to be more easily affected by obstacles, which makes communication between distant points difficult.Outline of the joint trialsTo address this issue, Fujitsu, DOCOMO and NTT will conduct joint trials of distributed MIMO(4), a wireless communication technology where multiple sub-terahertz wave antennas are dispersed to simultaneously emit radio waves from multiple directions to a receiving terminal.Through this joint experiment, the three companies aim to develop technology that is resistant to obstruction and realizes stable high-speed wireless communication over 100 Gbps.In order to realize high-speed and large-capacity communications at sub-terahertz waves with small size and low power consumption, Fujitsu aims to develop high-frequency wireless devices utilizing compound semiconductors such as gallium nitride (GaN) and indium phosphorus (InP). Moving forward, Fujitsu will promote the development of technologies for the realization of practical applications for 6G and actively engage in global 6G standardization activities to contribute to solving societal issues through R&D.Naoki Tani, Executive Vice President and Chief Technology Officer at DOCOMO, comments: "DOCOMO has been collaborating with Fujitsu since 2014 to verify wireless technologies towards the realization of 5G, and has leveraged the obtained know-how to provide 5G commercial services since 2020. We are delighted to collaborate with Fujitsu also towards the realization of the 6G concept. DOCOMO and NTT will initiate experimental trials with Fujitsu to establish 6G wireless technologies for sub-THz communication using 100 GHz and 300 GHz band, and make a solid contribution to 6G commercialization with a variety of industry partners."[1] NTT DOCOMO, INC.:Headquarters: Chiyoda-ku, Tokyo; President & CEO: Motoyuki Ii.[2] Nippon Telegraph and Telephone Corporation (NTT): Headquarters: Chiyoda-ku, Tokyo; President and CEO: Jun Sawada.[3] Compound semiconductor: A semiconductor consisting of two or more elements such as GaN (gallium nitride) and InP (indium phosphorus). Since the mobility of electrons is higher than that of silicon semiconductors, high-speed operation is possible.[4] Distributed MIMO: A technology that enables high-speed communication by simultaneously transmitting different signals from multiple distributed transmitting antennas and separating the signals received by multiple receiving antennas.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press Contacts:Fujitsu LimitedPublic and Investor Relations Divisionwww.fujitsu.com/global/about/resources/news/presscontacts/form/index.html Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech Sponsors Pre-ASCO China Summit Expert Panels on Early Phase Oncology Trials and Regulatory Strategy for China and US

SYDNEY, Jun 2, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, has sponsored expert panels at the Pre-ASCO China Summit 2022 bringing together leaders in oncology drug development in China and the US. The Pre-ASCO series was watched by more than 20,000 people globally.The Novotech sponsored Summit sessions are:- Go/No Go Decisions Based on Early Phase Oncology Trials (Watch here: https://tinyurl.com/novotech-webinars)- Development and Regulatory Strategy for China & US (Watch here: https://tinyurl.com/novotech-whitepapers)China offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations and world-class KOLs.-- According to Global Data whitepaper, EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5 (https://tinyurl.com/novotech-whitepapers)- Over the past 5 years, growth of oncology trials (CAGR of 25%) in China outpaced other countries.- This growth was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immuno-oncology, and leadership in cell therapy- China also recorded the largest number of new trials, followed by the US. In China, the number of new trials doubled during 2017-2021. Notably, China's regulatory reforms have accelerated drug approval by reducing the overall review and process.- In addition, over the last five years more 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%).- The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, low cost of conducting studies, high-quality standards and the presence of top clinical sites. Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.NCGS was established in 1984 in South Carolina and has a workforce of about 300 professionals across the US.Novotech CEO Dr. John Moller said:"This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.""Clients will receive seamless service, with a unified approach to systems and SOPs," Moller said.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.About Novotech Health HoldingsNovotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials

SYDNEY, May 12, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its CRO services to the US, is pleased to sponsor the Pre-ASCO China Summit 2022 event titled: Go/No Go Decisions Based on Early Phase Oncology Trials ('The Summit').The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:- Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech- Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech ChinaRegister here: https://www.eventbrite.com/e/pre-asco-china-2-gono-go-decisions-based-on-early-phase-oncology-trials-tickets-330427145487Event Date:- China Time: 9:00-10:30 AM, Saturday, May 14, 2022- US EST Time: 9:00-10:30 PM, Friday, May 13, 2022- US PST Time: 6:00-7:30 PM, Friday, May 13, 2022Language: English, with Chinese simultaneous translationVenue: Live Zoom WebinarModerator:- Dr. Li Yan, CMO, Brii Biosciences; Managing Director, United States Chinese Anti-Cancer Association (USCACA)The Summit will start with a presentation by Novotech's Senior Medical Monitor Dr. Ramandeep Sharma titled: Approaches, Experiences, and considerations for early phase go/no go.A panel discussion will follow featuring leading clinical specialists including:- Dr. Jin Li, Shanghai East Hospital- Dr. Li Yan, CMO, Brii Biosciences; Managing Director, USCACA- Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech- Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China- Dr. Xiaoxia Yan, Highthink- Dr. Jianmin Fang, Co-founder, CEO & CSO, RemeGen- Dr. Joseph Eid, Chief Medical Officer, Hengrui- Dr. Jon Wigginton, Senior Advisor and Chairman SAB, Cullinan Oncology; Former Head of Immuno-Oncology Early Clinical Development, BMSEarlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.NCGS was established in 1984 in South Carolina with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.Novotech CEO Dr. John Moller said:"This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs." "Clients will receive seamless service, with a unified approach to systems and SOPs well developed," Moller said. Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.About Novotech Health HoldingsNovotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC

ADELAIDE, AUS, Apr 19, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence.Avance Clinical has undergone significant expansion in recent years, including new offices in Sydney and Melbourne to accommodate the growing clinical team in Australia.The award winner will be announced on 1 September 2022. The finalists are:- Avance Clinical- Calyx- CMIC Group- EPS- ICON- Parexel- Syneos HealthAvance Clinical's CEO Yvonne Lungershausen said:"Avance Clinical is extremely pleased to be selected as a finalist for this prestigious award. It is a credit to our amazing customer-focused team for delivering the CRO excellence that has been recognized by the Informa Pharma Intelligence award judges."Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients. We are very proud of our growth and success in APAC in recent years."According to Informa Pharma Intelligence:This Award is to recognize CROs that provide full or specialist services to their clients and which have an office in either in Japan or the Asia region including Australia.Judging considers the quality of services and relationships built with clients and pays particular attention to the innovative patient recruitment strategies the CRO has brought to the table.The award is based on achievements in the 2021 calendar year.Core areas judged include:- The particular capabilities and strengths the CRO offers- How the company has delivered results that exceed sponsor expectations- Innovations in patient recruitment strategy has the CRO brought to its partner- How it has improved its performance, for example, in its quality of data, timelines and transparency- The steps the company is taking towards streamlining data collection and reportingTo find out more please visit: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m."With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions," said Lungershausen.Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.com About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More